Welcome to our dedicated page for Cytodyn news (Ticker: CYDY), a resource for investors and traders seeking the latest updates and insights on Cytodyn stock.
CytoDyn Inc. reports developments for leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor. The company is a clinical-stage oncology issuer focused on CCR5 biology in difficult-to-treat cancers, including metastatic triple-negative breast cancer and metastatic colorectal cancer.
Recurring news includes clinical and translational data presentations, Phase 2 colorectal cancer study updates, expanded access activity for triple-negative breast cancer, and preclinical work in glioblastoma. Company updates also cover financing actions used to support leronlimab development and corporate webcasts addressing scientific, operational, clinical, and financial progress.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
CytoDyn Inc. (OTCQB: CYDY) announced an upcoming webcast for the investment community scheduled on April 11, 2023, at 1:00 PM PT / 4:00 PM ET. The update will feature key executives, including Board Chair Tanya Urbach and President Cyrus Arman, discussing the company’s progress and the potential of leronlimab, a CCR5 antagonist. Questions can be submitted prior to the event until Noon PT on April 7, 2023, and will be addressed during the presentation if appropriate. A replay will be available approximately one hour after the event until May 11, 2023.
CytoDyn Inc. (OTCQB: CYDY) will hold a webcast on December 29, 2022, at 8:00 a.m. PT to discuss the performance of its investigational drug, leronlimab, in clinical trials. The discussion will also address recent charges against former CEO Nader Pourhassan, who was terminated on January 24, 2022, and has since had no association with the company. CytoDyn is focused on developing leronlimab for various therapeutic applications, including infectious diseases, cancer, and autoimmune conditions. The webcast replay will be available until January 29, 2023.
CytoDyn Inc. (OTCQB: CYDY) will host a virtual R&D Update on December 7, 2022, at 11:00 a.m. ET. The event will feature presentations by key management and Scientific Advisory Board members discussing the clinical development of leronlimab, a CCR5 antagonist. Presenters include Cyrus Arman, M.D., who will overview the R&D strategy; Mazen Noureddin, M.D., discussing leronlimab's potential in treating NASH; Stefan Glück, M.D., focused on cancer therapy; and Jonah Sacha, Ph.D., on HIV research. The event can be accessed via the company's website.
CytoDyn (OTCQB: CYDY) announced the voluntary withdrawal of its Biologics License Application (BLA) for leronlimab, aimed at treating HIV-MDR patients. The decision stems from concerns over data quality from a clinical research organization (CRO). Despite meeting primary endpoints in trials, the company believes FDA approval is unlikely without substantial investments. CytoDyn plans to respond to a clinical hold and continue exploring leronlimab's effectiveness in other areas, including NASH and oncology, where promising results have been observed. A webcast will provide further updates on these developments.